Compounds > triazoles
Page last updated: 2024-08-24

triazoles and vlx600

triazoles has been researched along with vlx600 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
D'Arcy, P; Dang, L; De Milito, A; Fayad, W; Fryknäs, M; Gogvadze, V; Gullbo, J; Hernlund, E; Larsson, R; Linder, S; Nygren, P; Olofsson, MH; Påhlman, S; Rickardson, L; Schughart, LA; Zhang, X1
Bao, G; Gong, P; Wang, L; Xi, S; Zhai, X; Zhang, Y; Zhao, S; Zhou, G1
Brandt, P; Bremberg, U; D'Arcy, P; Fryknäs, M; Gullbo, J; Larsson, R; Linder, S; Nygren, P; Olofsson, MH; Persson, I; Schughart, LK; Senkowski, W; Zhang, X1
Choi, MY; Cook, DR; Elledge, SJ; Haigis, KM; Li, MZ; Martin, TD1
Antonescu, CR; Balachandran, VP; Bowler, TG; Cross, JR; DeMatteo, RP; Liu, M; Loo, JK; Medina, BD; Moral, AJ; Param, NJ; Rossi, F; Vitiello, GA; Zeng, S; Zhang, JQ; Zhao, JN1
Borad, M; Gulbo, J; Mansfield, AS; Mody, K; Nygren, P; Vemireddy, L1
Correia, C; Dowdy, SC; Ekstrom, TL; Heinzen, EP; Hitosugi, T; Hou, X; Huntoon, CJ; Kanakkanthara, A; Karnitz, LM; Kaufmann, SH; Kurmi, K; Li, H; O'Brien, D; Oberg, AL; Purfeerst, ER; Wahner Hendrickson, AE; Weroha, SJ1
Ekstrom, TL; Huehls, AM; Kanakkanthara, A; Karnitz, LM; Pathoulas, NM1

Trials

1 trial(s) available for triazoles and vlx600

ArticleYear
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.
    Investigational new drugs, 2019, Volume: 37, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Hydrazones; Iron Chelating Agents; Male; Middle Aged; Neoplasms; Triazoles

2019

Other Studies

7 other study(ies) available for triazoles and vlx600

ArticleYear
Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.
    Nature communications, 2014, Volume: 5

    Topics: Animals; Antineoplastic Agents; Autophagy; Drug Screening Assays, Antitumor; Female; Glucose; Glycolysis; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Hypoxia; Mice; Mitochondria; Oxidative Phosphorylation; Spheroids, Cellular; Triazoles; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2014
Design, Synthesis, and Cytotoxicity of Novel 2,4,6-Trisubstituted 1,3,5- triazines Bearing Aryl Hydrazone Moiety as Potent Antitumor Agent.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2016, Volume: 12, Issue:7

    Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazones; Structure-Activity Relationship; Triazines; Triazoles

2016
Iron chelators target both proliferating and quiescent cancer cells.
    Scientific reports, 2016, 12-07, Volume: 6

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Dose-Response Relationship, Drug; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Inhibitory Concentration 50; Iron Chelating Agents; MCF-7 Cells; Mitochondria; Ribonucleotide Reductases; Structure-Activity Relationship; Triazoles

2016
A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells.
    Cell reports, 2017, 07-11, Volume: 20, Issue:2

    Topics: Animals; Cell Line; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Female; Genes, ras; HCT116 Cells; Humans; Hydrazones; Mice; Mice, Inbred BALB C; Minocycline; Mutation; NADH Dehydrogenase; Proto-Oncogene Proteins; Tigecycline; Triazoles; Xenograft Model Antitumor Assays

2017
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2018
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer research, 2019, 12-01, Volume: 79, Issue:23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclin-Dependent Kinases; DNA Methylation; Energy Metabolism; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazones; Hydroxybenzoates; Mice; Mitochondria; Mutation; Nicotinamide N-Methyltransferase; Ovarian Neoplasms; Ovary; Oxidative Phosphorylation; Promoter Regions, Genetic; Tigecycline; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays

2019
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.
    Molecular cancer therapeutics, 2021, Volume: 20, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Histone Demethylases; Homologous Recombination; Humans; Hydrazones; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Triazoles; Tumor Cells, Cultured

2021